Single, large trial in HIV risk reduction and vaginal microbicides acceptable -- joint cmte..
This article was originally published in The Tan Sheet
Executive Summary
VAGINAL MICROBICIDE HIV RISK REDUCTION COULD BE TESTED IN SINGLE, LARGE TRIAL, members of FDA's Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees agreed Nov. 21 at a joint meeting in Gaithersburg, Md. As envisioned by the committee, such a study would evaluate the safety and efficacy of vaginal microbicides in preventing HIV transmission and might include data from both domestic study sites and international high-risk groups.